Analgesic Effect of Illiohypogastic & Ilioinguinal Nerve Block in TAVR - TF (Prospective Randomized Study)
1 other identifier
interventional
52
1 country
2
Brief Summary
The purpose of the study is to compare the effect of illiohypogastric and ilioinguinal nerve block with the local infiltration with lidocaine in patients undergoing TAVI
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1
Started Jan 2024
Shorter than P25 for phase_1
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 2, 2024
CompletedFirst Submitted
Initial submission to the registry
April 9, 2024
CompletedFirst Posted
Study publicly available on registry
April 12, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 15, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2024
CompletedApril 12, 2024
April 1, 2024
7 months
April 9, 2024
April 9, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Extra Demand of sedation
Need for increments of narcotics or propofol will be recorded and collected at the end of the procedure.
All through procedure
Secondary Outcomes (1)
Patient and surgeon satisfaction
all through the procedure
Study Arms (2)
Group A:Lidocaine group
ACTIVE COMPARATORwill receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%
Group B:Bupivacaine group
ACTIVE COMPARATORwill receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivicane 0.25% by an experienced anesthesiologist
Interventions
* Group (A) lidocaine : will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%.
• Group (B),bupivacaine: will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivacaine 0.25% by an experienced anesthesiologist
Eligibility Criteria
You may qualify if:
- Patients fulfilling criteria for TAVI regarding age \& pathology of aortic valve will be included in the study.
You may not qualify if:
- Refusal of the patients, Patients with neurological disease (Disturbed conscious level or psychiatric illness) severe respiratory disease need mechanical ventilation or need respiratory support, coagulation abnormalities, infection at site of injection.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
maha sadek El Derh
Cairo, Heliopolis, 11721, Egypt
Ain Shams University
Cairo, Egypt
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- * Group (A): will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1% (9). * Group (B): will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivicane 0.25% by an experienced anesthesiologist.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor of Anesthesia
Study Record Dates
First Submitted
April 9, 2024
First Posted
April 12, 2024
Study Start
January 2, 2024
Primary Completion
July 15, 2024
Study Completion
August 30, 2024
Last Updated
April 12, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share